BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-1 out of 1 found
  Current Search:  remodulin: 1     

HTML
100%
Auriga Maintains a 'Buy' on United Therapeutics (UTHR); Named as Best 2010 Biotechnology Idea
Auriga maintains a 'Buy' on United Therapeutics (Nasdaq: UTHR), names stock as Best 2010 Biotechnology Idea.

Price target increased from $54 to $70.

Auriga analyst says, "Based on our checks, we are increasing our Tyvaso numbers for Q4 2009 from $5.3MM to ...

Street Insider:  Jan 13 2010 4:46PM
Matching: remodulin
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.